This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAmyris (3A01) 주식 개요Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. 자세히 보기3A01 펀더멘털 분석스노우플레이크 점수가치 평가3/6미래 성장2/6과거 실적0/6재무 건전성2/6배당0/6강점수익은 연간 27.43% 증가할 것으로 예상됩니다.동종업계 및 업계 대비 좋은 가치로 거래위험 분석의미 있는 시가총액이 없습니다(€37K)마이너스 주주 지분주식은 유동성이 매우 낮습니다지난 1년 동안 주주가 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기3A01 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.03998.7% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-620m901m2016201920222025202620282031Revenue US$901.3mEarnings US$85.7mAdvancedSet Fair ValueView all narrativesFeatured narrative•Materials opportunityUpside Gold2 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 저평가 내재 할인율An Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative14.5kusers have viewed this narrative41users have liked this narrative1users have commented on this narrative284users have followed this narrativeRead narrativeAmyris, Inc. 경쟁사Bio-GateSymbol: DB:BIG1Market cap: €7.1mOTI GreentechSymbol: DUSE:NSAKMarket cap: €311.5kBRAIN BiotechSymbol: XTRA:BNNMarket cap: €71.0mPlasma SystemSymbol: WSE:PSMMarket cap: zł878.7k가격 이력 및 성과Amyris 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.03952주 최고가US$2.1952주 최저가US$0.036베타1.281개월 변동0%3개월 변동-39.66%1년 변동-98.05%3년 변동-97.98%5년 변동-98.85%IPO 이후 변동-99.98%최근 뉴스 및 업데이트공지 • May 08+ 3 more updatesKathy L. Fortmann to Join Amyris, Inc. as Member of the Board of DirectorsAmyris, Inc. announced that Ms. Kathy L. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris. Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients. She most recently served as Chief Executive Officer of ACOMO N.V. from 2021 to 2023. Prior to that, Ms. Fortmann held various roles at International Flavors & Fragrances Inc. ("IFF") from 2020 until 2021, including Division President of Nourish, Division Chief Executive Officer, Taste, and Head, Taste Strategy and Cross Fertilization. Prior to IFF, she was a senior executive at FrieslandCampina from 2017 to 2019, serving as Business Group President, Ingredients and a member of the Executive Committee. From 2005 until 2017, Ms. Fortmann held various leadership positions at Cargill, Incorporated. Prior to Cargill, she held positions of increasing responsibility at E.I. DuPont de Nemours, Inc. from 1989 until 2005. Ms. Fortmann currently serves as a director on the boards of FMC Corporation and PPG.공지 • Apr 03Amyris, Inc. announced delayed annual 10-K filingOn 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Jan 24Third Amended Joint Reorganization Plan Filed by Amyris, Inc.Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding.공지 • Jan 06Foris Ventures Provides Information to the ShareholdersOn January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets.공지 • Dec 28Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities.공지 • Nov 14Amyris, Inc. announced delayed 10-Q filingOn 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.더 많은 업데이트 보기Recent updates공지 • May 08+ 3 more updatesKathy L. Fortmann to Join Amyris, Inc. as Member of the Board of DirectorsAmyris, Inc. announced that Ms. Kathy L. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris. Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients. She most recently served as Chief Executive Officer of ACOMO N.V. from 2021 to 2023. Prior to that, Ms. Fortmann held various roles at International Flavors & Fragrances Inc. ("IFF") from 2020 until 2021, including Division President of Nourish, Division Chief Executive Officer, Taste, and Head, Taste Strategy and Cross Fertilization. Prior to IFF, she was a senior executive at FrieslandCampina from 2017 to 2019, serving as Business Group President, Ingredients and a member of the Executive Committee. From 2005 until 2017, Ms. Fortmann held various leadership positions at Cargill, Incorporated. Prior to Cargill, she held positions of increasing responsibility at E.I. DuPont de Nemours, Inc. from 1989 until 2005. Ms. Fortmann currently serves as a director on the boards of FMC Corporation and PPG.공지 • Apr 03Amyris, Inc. announced delayed annual 10-K filingOn 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Jan 24Third Amended Joint Reorganization Plan Filed by Amyris, Inc.Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding.공지 • Jan 06Foris Ventures Provides Information to the ShareholdersOn January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets.공지 • Dec 28Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities.공지 • Nov 14Amyris, Inc. announced delayed 10-Q filingOn 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Sep 08Nasdaq to Delist the Common Stock of AmyrisOn September 7, 2023, The Nasdaq Stock Market announced that it will delist the common stock of Amyris, Inc. Amyris, Inc.’s securities were suspended on August 21, 2023, and have not traded on Nasdaq since that time.공지 • Sep 02Amyris, Inc. Appoints Scott White as A Class II DirectorOn August 29, 2023, Amyris Inc. appointed Scott White as a Class II director, effective immediately, and with a term expiring at the company’s 2024 annual meeting of stockholders. The board determined that Mr. White qualifies as an independent director pursuant to the listing standards of the Nasdaq Stock Market. Mr. White will serve as a member of the Restructuring Committee of the Board. Mr. White is currently President and Chief Executive Officer of Edsal Manufacturing, where he has served since 2019. Mr. White has over 30 years of experience in global finance, marketing and general management roles. Prior to joining Edsal, from 2016 to 2019, Mr. White served as CEO of New Avon, a leading provider of cosmetics and beauty products. Prior to that, from 2005 to 2016, he held multiple senior management roles over 10 years at Abbott Laboratories, including President of Abbott Nutrition International. Mr. White began his career at Procter & Gamble where he served for 15 years. Mr. White currently serves as a member of the board of directors of Edsal, a privately held company. Mr. White holds an M.B.A. from Northwestern University Kellogg School of Management and a B.S. in Finance from Miami University.공지 • Aug 23+ 1 more updateMotion for Joint Administration Filed by Amyris, Inc.Amyris, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on August 21, 2023. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Clean Beauty Collaborative Inc., Clean Beauty 4U Holdings, LLC and Clean Beauty 4U LLC, with its own case for administrative and procedural purposes. Amyris, Inc. has been proposed as the lead debtor.공지 • Aug 12Amyris' Common Stock To Be Delisted from NasdaqAs previously disclosed, on August 10, 2023, Amyris, Inc. (the “Company”) and certain of its direct and indirect subsidiaries filed a voluntary petition for relief (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. On August 10, 2023, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filings and associated public concerns raised by them, concerns regarding the residual equity interest of the existing listed securities holders and concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on August 21, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.공지 • Aug 11+ 4 more updatesAmyris, Inc. announced delayed 10-Q filingOn 08/10/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Aug 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €22.2m (US$24.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$540m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Negative equity (-US$648m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$159m net loss in 2 years). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€22.2m market cap, or US$24.3m).공지 • Jun 27+ 1 more updateAmyris, Inc. Announces Executive ChangesAmyris, Inc. announced that John Melo has resigned from his role as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer.공지 • May 29Amyris Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price RequirementOn May 26, 2023, Amyris, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the ‘Minimum Bid Price Requirement’). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock which will continue to trade on The Nasdaq Global Select Market under the symbol ‘AMRS’. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 22, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 22, 2023, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by November 22, 2023, the Company’s common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 22, 2023, including such options as effecting a reverse stock split.Reported Earnings • May 10First quarter 2023 earnings released: US$0.53 loss per share (vs US$0.34 loss in 1Q 2022)First quarter 2023 results: US$0.53 loss per share (further deteriorated from US$0.34 loss in 1Q 2022). Revenue: US$56.1m (down 2.8% from 1Q 2022). Net loss: US$193.3m (loss widened 80% from 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Buying Opportunity • Apr 26Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 52%. The fair value is estimated to be €0.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 36%. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings is also forecast to grow by 31% per annum over the same time period.Reported Earnings • Mar 18Full year 2022 earnings released: US$1.65 loss per share (vs US$0.93 loss in FY 2021)Full year 2022 results: US$1.65 loss per share (further deteriorated from US$0.93 loss in FY 2021). Revenue: US$269.8m (down 21% from FY 2021). Net loss: US$528.5m (loss widened 95% from FY 2021). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Breakeven Date Change • Mar 18No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$43.8m in 2025.공지 • Jan 31Amyris Launches 4U by Tia™ Haircare Line Exclusively At WalmartAmyris, Inc. announced the launch of 4U by TiaTM, a new haircare line available exclusively at Walmart. Founded by actress and entrepreneur Tia Mowry, 4U by Tia will be sold in over 2,800 Walmart retail stores in the U.S, on Walmart.com, and on the direct-to-consumer website 4UbyTia.com. Amyris will be operating the brand as part of its clean beauty portfolio of brands. The brand is launching with a full line of eight products formulated for 2A to 4C (curly) hair, all of which contain Amyris' patented Hemi15TM, a breakthrough ingredient that nourishes and protects textured hair. The line is 100% vegan, silicone-free, sulfate-free and paraben-free. Hemi15 is created using Amyris' proprietary Lab-to-Market platform, which leverages precision fermentation to create molecules that are bioidentical to those found in nature and traditionally derived from finite sources (including animals, plants, or petrochemicals) to create sustainable ingredients and provide better, healthier options for the products people use every day.Breakeven Date Change • Nov 16No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024.Breakeven Date Change • Nov 11No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$78.1m in 2024.Reported Earnings • Nov 10Third quarter 2022 earnings released: US$0.50 loss per share (vs US$0.11 loss in 3Q 2021)Third quarter 2022 results: US$0.50 loss per share (further deteriorated from US$0.11 loss in 3Q 2021). Revenue: US$71.1m (up 49% from 3Q 2021). Net loss: US$161.4m (loss widened 390% from 3Q 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Breakeven Date Change • Nov 09Forecast to breakeven in 2024The 7 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 45% per year to 2023. The company is expected to make a profit of US$54.2m in 2024. Average annual earnings growth of 88% is required to achieve expected profit on schedule.Recent Insider Transactions • Sep 09CFO & Chief Administration Officer recently sold €74k worth of stockOn the 2nd of September, Hermanus Kieftenbeld sold around 26k shares on-market at roughly €2.86 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €116k. Hermanus has been a net seller over the last 12 months, reducing personal holdings by €150k.Recent Insider Transactions • Aug 18President recently bought €68k worth of stockOn the 15th of August, John Melo bought around 17k shares on-market at roughly €3.96 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by €48k.Reported Earnings • Aug 11Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.048 profit in 2Q 2021)Second quarter 2022 results: US$0.34 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$65.2m (up 25% from 2Q 2021). Net loss: US$110.0m (down US$125.4m from profit in 2Q 2021). Over the next year, revenue is forecast to grow 91%, compared to a 3.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 11Forecast to breakeven in 2024The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.Recent Insider Transactions • Jul 09President recently sold €116k worth of stockOn the 6th of July, John Melo sold around 56k shares on-market at roughly €2.08 per share. This was the largest sale by an insider in the last 3 months. This was John's only on-market trade for the last 12 months.Recent Insider Transactions • Jun 06CFO & Chief Administration Officer recently sold €76k worth of stockOn the 2nd of June, Hermanus Kieftenbeld sold around 35k shares on-market at roughly €2.18 per share. This was the largest sale by an insider in the last 3 months. Hermanus has been a seller over the last 12 months, reducing personal holdings by €382k.공지 • May 04Amyris, Inc. to Report Q1, 2022 Results on May 10, 2022Amyris, Inc. announced that they will report Q1, 2022 results Pre-Market on May 10, 2022공지 • Apr 24Amyris, Inc. (NasdaqGS:AMRS) entered into an Agreement and Plan of Merger and Reorganization to acquire Onda Beauty Inc.Amyris, Inc. (NasdaqGS:AMRS) entered into an Agreement and Plan of Merger and Reorganization to acquire Onda Beauty Inc. on April 11, 2022. The consideration consists of 907,946 shares of the common stock of Amyris, Inc. Fenwick & West LLP acted as legal advisor for Amyris.공지 • Apr 12Amyris, Inc., Annual General Meeting, May 27, 2022Amyris, Inc., Annual General Meeting, May 27, 2022, at 14:00 Pacific Standard Time. Agenda: To consider election of three Class III Directors to serve for a three-year term; to consider ratification of the appointment of Independent Registered Public Accounting Firm; and to consider approval of amendment to Certificate of Incorporation to increase authorized shares.공지 • Mar 04Amyris, Inc. announced delayed annual 10-K filingOn 03/02/2022, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Feb 24Amyris, Inc. to Report Q4, 2021 Results on Mar 01, 2022Amyris, Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 01, 2022공지 • Feb 10Amyris, Inc. (NasdaqGS:AMRS) completed the acquisition of 70% of EcoFabulous Cosmetics.Amyris, Inc. (NasdaqGS:AMRS) agreed to acquire 70% of EcoFabulous Cosmetics on April 15, 2021. Marissa will join Amyris to lead brand innovation and be the Chief Creative Officer for the EcoFabulous brand. Amyris, Inc. (NasdaqGS:AMRS) completed the acquisition of 70% of EcoFabulous Cosmetics on February 9, 2022.공지 • Dec 11Federman & Sherwood Announces Certification of Securities Class Action Lawsuit Against Amyris, IncFederman & Sherwood announced that on December 8, 2021, a class action lawsuit was certified in the United States District Court for the Northern District of California against Amyris, Inc. its CEO John Melo, and its former CFO Kathleen Valiasek. The court certified a Class of investors who purchased shares of Amyris, Inc. common stock during the period from March 15, 2018 through March 19, 2019 (the Class Period) and who were damaged thereby. The lawsuit alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations that defendants issued a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period. The lawsuit seeks to recover damages on behalf of Amyris, Inc. investors who purchased common stock during the Class Period and are therefore a member of the Class.공지 • Nov 24Amyris, Inc. Provides Revenue Guidance for the Full Year 2021Amyris, Inc. provides revenue guidance for the full year 2021. For the year, the company expects revenue estimate of $330 million to $370 million.공지 • Aug 27Amyris, Inc. and Jonathan Van Ness Launch JVN Hair A Transformation in Clean Hair ProductsAmyris, Inc. announced the launch of JVN™, a clean hair products brand. The launch is the third of three highly anticipated brand launches Amyris is introducing to the market this summer. The JVN haircare line is a collaboration between Amyris and Jonathan Van Ness: hair stylist, Emmy-nominated television personality, New York Times best-selling author and podcaster. The JVN line sees all beauty, serves all beauty and honors the uniqueness of each person. The JVN collection features four accessibly priced, best performing in category product families that are silicone-free, color-safe, sulfate-free, cruelty-free, and vegan: Nurture, for hair that deserves extra moisture; Undamage, for hair that is stressed or overtreated, Embody, for fine hair with big dreams; and Complete, for hair that is ready to style.공지 • Aug 25+ 1 more updateAmyris, Inc. (NasdaqGS:AMRS) completed the acquisition of MG Empower Ltd.Amyris, Inc. (NasdaqGS:AMRS) entered into an agreement to acquire Mg Empower Limited on August 11, 2021. In a related transaction, Amyris, Inc entered into an Plan of Merger and Reorganization with OLIKA Inc and Note Purchase Agreement with Olika. Amyris, Inc. (NasdaqGS:AMRS) completed the acquisition of MG Empower Ltd on August 24, 2021.공지 • Aug 21Amyris Achieves Promising In-Vivo Results For Intranasal Delivery Of RNA/NLC VaccineAmyris, Inc. announced promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute (IDRI). Current mRNA vaccine technologies are providing limited immunity protection for the upper respiratory system. As a result, vaccinated people may experience viral replication and viral shedding regardless of variants. In-vivo results indicate that, when delivered to the mucosal membranes via intranasal administration, the Amyris/IDRI RNA vaccine generates antibodies and provides upper respiratory protection for SARS-CoV-2 (COVID-19), which Amyris believes has the potential to provide fuller protection against current variants of SARS-CoV-2. The Amyris/IDRI RNA technology may also support the potential for intranasal vaccine delivery that can protect against SARS-CoV-2 and other respiratory diseases, including the flu. If approved and commercialized, the Amyris/IDRI RNA vaccine is targeted to be more accessible to people in underserved countries. In addition, the intranasal vaccine may offer improved upper respiratory protection beyond currently approved vaccines. Amyris will provide a detailed update of the progress of its vaccine platform and a roadmap for scale up and delivery during one of its upcoming investor mini-series webinars.공지 • Aug 20+ 1 more updateAmyris, Inc. (NasdaqGS:AMRS) entered into an agreement to acquire Mg Empower Limited.Amyris, Inc. (NasdaqGS:AMRS) entered into an agreement to acquire Mg Empower Limited on August 11, 2021. In a related, transaction Amyris, Inc entered into an Plan of Merger and Reorganization with OLIKA Inc and Note Purchase Agreement with Olika.공지 • Jun 28+ 2 more updatesAmyris, Inc.(NasdaqGS:AMRS) dropped from Russell Microcap Growth IndexAmyris, Inc.(NasdaqGS:AMRS) dropped from Russell Microcap Growth Index주주 수익률3A01DE ChemicalsDE 시장7D0%-1.6%3.4%1Y-98.1%5.5%3.4%전체 주주 수익률 보기수익률 대 산업: 3A01은 지난 1년 동안 5.5%의 수익을 기록한 German Chemicals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 3A01은 지난 1년 동안 3.4%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is 3A01's price volatile compared to industry and market?3A01 volatility3A01 Average Weekly Movementn/aChemicals Industry Average Movement5.7%Market Average Movement6.0%10% most volatile stocks in DE Market12.5%10% least volatile stocks in DE Market2.7%안정적인 주가: 3A01의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine 3A01의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트20031,598Han Kieftenbeldamyris.com더 보기Amyris, Inc. 기초 지표 요약Amyris의 순이익과 매출은 시가총액과 어떻게 비교됩니까?3A01 기초 통계시가총액€34.11k순이익 (TTM)-€563.42m매출 (TTM)€245.91m0.0x주가매출비율(P/S)0.0x주가수익비율(P/E)3A01는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표3A01 손익계산서 (TTM)매출US$268.22m매출원가US$369.78m총이익-US$101.55m기타 비용US$512.99m순이익-US$614.55m최근 보고된 실적Mar 31, 2023다음 실적 발표일해당 없음주당순이익(EPS)-1.65총이익률-37.86%순이익률-229.12%부채/자본 비율-145.2%3A01의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/11/19 03:56종가2023/08/24 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Amyris, Inc.는 15명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관J. HorwitzBairdCarter DriscollB. Riley Securities, Inc.Susan AndersonCanaccord Genuity12명의 분석가 더 보기
Featured narrative•Materials opportunityUpside Gold2 months ago author updated this narrativeSTFair Value from stuart_robertsCA$5.0768.0% 저평가 내재 할인율An Undervalued 3.3Moz Gold Project in CanadaKey takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read full narrative14.5kusers have viewed this narrative41users have liked this narrative1users have commented on this narrative284users have followed this narrativeRead narrative
공지 • May 08+ 3 more updatesKathy L. Fortmann to Join Amyris, Inc. as Member of the Board of DirectorsAmyris, Inc. announced that Ms. Kathy L. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris. Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients. She most recently served as Chief Executive Officer of ACOMO N.V. from 2021 to 2023. Prior to that, Ms. Fortmann held various roles at International Flavors & Fragrances Inc. ("IFF") from 2020 until 2021, including Division President of Nourish, Division Chief Executive Officer, Taste, and Head, Taste Strategy and Cross Fertilization. Prior to IFF, she was a senior executive at FrieslandCampina from 2017 to 2019, serving as Business Group President, Ingredients and a member of the Executive Committee. From 2005 until 2017, Ms. Fortmann held various leadership positions at Cargill, Incorporated. Prior to Cargill, she held positions of increasing responsibility at E.I. DuPont de Nemours, Inc. from 1989 until 2005. Ms. Fortmann currently serves as a director on the boards of FMC Corporation and PPG.
공지 • Apr 03Amyris, Inc. announced delayed annual 10-K filingOn 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Jan 24Third Amended Joint Reorganization Plan Filed by Amyris, Inc.Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding.
공지 • Jan 06Foris Ventures Provides Information to the ShareholdersOn January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets.
공지 • Dec 28Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities.
공지 • Nov 14Amyris, Inc. announced delayed 10-Q filingOn 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • May 08+ 3 more updatesKathy L. Fortmann to Join Amyris, Inc. as Member of the Board of DirectorsAmyris, Inc. announced that Ms. Kathy L. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris. Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients. She most recently served as Chief Executive Officer of ACOMO N.V. from 2021 to 2023. Prior to that, Ms. Fortmann held various roles at International Flavors & Fragrances Inc. ("IFF") from 2020 until 2021, including Division President of Nourish, Division Chief Executive Officer, Taste, and Head, Taste Strategy and Cross Fertilization. Prior to IFF, she was a senior executive at FrieslandCampina from 2017 to 2019, serving as Business Group President, Ingredients and a member of the Executive Committee. From 2005 until 2017, Ms. Fortmann held various leadership positions at Cargill, Incorporated. Prior to Cargill, she held positions of increasing responsibility at E.I. DuPont de Nemours, Inc. from 1989 until 2005. Ms. Fortmann currently serves as a director on the boards of FMC Corporation and PPG.
공지 • Apr 03Amyris, Inc. announced delayed annual 10-K filingOn 04/02/2024, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Jan 24Third Amended Joint Reorganization Plan Filed by Amyris, Inc.Amyris, Inc. filed third amended joint plan of reorganization in the US Bankruptcy Court on January 22, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding. Amyris, Inc. filed modified third amended joint plan of reorganization in the US Bankruptcy Court on January 23, 2024. As per the plan filed, there is no change in treatment of any claim class or source of funding.
공지 • Jan 06Foris Ventures Provides Information to the ShareholdersOn January 5, 2024, Foris Ventures, LLC announced that it has been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. Foris Ventures may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, Foris Ventures may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets.
공지 • Dec 28Amyris, Inc. Announces Resignation of Elizabeth Dreyer as Chief Accounting Officer and Corporate Controller, Effective as of January 2, 2024Amyris, Inc. announced that on December 20, 2023, Elizabeth Dreyer notified the Company of her decision to resign from her position as the Company’s Chief Accounting Officer and Corporate Controller effective as of January 2, 2024 (the “Resignation Date”) to take up a similar role at another publicly listed company. Ms. Dreyer’s resignation is not due to any disagreements on the Company’s financial statement disclosures, internal controls or accounting policies or practices. Ms. Dreyer will assist the Company with the transition of her duties and responsibilities.
공지 • Nov 14Amyris, Inc. announced delayed 10-Q filingOn 11/13/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Sep 08Nasdaq to Delist the Common Stock of AmyrisOn September 7, 2023, The Nasdaq Stock Market announced that it will delist the common stock of Amyris, Inc. Amyris, Inc.’s securities were suspended on August 21, 2023, and have not traded on Nasdaq since that time.
공지 • Sep 02Amyris, Inc. Appoints Scott White as A Class II DirectorOn August 29, 2023, Amyris Inc. appointed Scott White as a Class II director, effective immediately, and with a term expiring at the company’s 2024 annual meeting of stockholders. The board determined that Mr. White qualifies as an independent director pursuant to the listing standards of the Nasdaq Stock Market. Mr. White will serve as a member of the Restructuring Committee of the Board. Mr. White is currently President and Chief Executive Officer of Edsal Manufacturing, where he has served since 2019. Mr. White has over 30 years of experience in global finance, marketing and general management roles. Prior to joining Edsal, from 2016 to 2019, Mr. White served as CEO of New Avon, a leading provider of cosmetics and beauty products. Prior to that, from 2005 to 2016, he held multiple senior management roles over 10 years at Abbott Laboratories, including President of Abbott Nutrition International. Mr. White began his career at Procter & Gamble where he served for 15 years. Mr. White currently serves as a member of the board of directors of Edsal, a privately held company. Mr. White holds an M.B.A. from Northwestern University Kellogg School of Management and a B.S. in Finance from Miami University.
공지 • Aug 23+ 1 more updateMotion for Joint Administration Filed by Amyris, Inc.Amyris, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on August 21, 2023. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Clean Beauty Collaborative Inc., Clean Beauty 4U Holdings, LLC and Clean Beauty 4U LLC, with its own case for administrative and procedural purposes. Amyris, Inc. has been proposed as the lead debtor.
공지 • Aug 12Amyris' Common Stock To Be Delisted from NasdaqAs previously disclosed, on August 10, 2023, Amyris, Inc. (the “Company”) and certain of its direct and indirect subsidiaries filed a voluntary petition for relief (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. On August 10, 2023, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filings and associated public concerns raised by them, concerns regarding the residual equity interest of the existing listed securities holders and concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on August 21, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq.
공지 • Aug 11+ 4 more updatesAmyris, Inc. announced delayed 10-Q filingOn 08/10/2023, Amyris, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Aug 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €22.2m (US$24.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$540m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Negative equity (-US$648m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$159m net loss in 2 years). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€22.2m market cap, or US$24.3m).
공지 • Jun 27+ 1 more updateAmyris, Inc. Announces Executive ChangesAmyris, Inc. announced that John Melo has resigned from his role as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer.
공지 • May 29Amyris Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price RequirementOn May 26, 2023, Amyris, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the ‘Minimum Bid Price Requirement’). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock which will continue to trade on The Nasdaq Global Select Market under the symbol ‘AMRS’. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 22, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before November 22, 2023, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, the Staff will provide written confirmation that the Company has achieved compliance. If the Company does not regain compliance with the Minimum Bid Price Requirement by November 22, 2023, the Company’s common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by the Staff to a hearings panel. The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by November 22, 2023, including such options as effecting a reverse stock split.
Reported Earnings • May 10First quarter 2023 earnings released: US$0.53 loss per share (vs US$0.34 loss in 1Q 2022)First quarter 2023 results: US$0.53 loss per share (further deteriorated from US$0.34 loss in 1Q 2022). Revenue: US$56.1m (down 2.8% from 1Q 2022). Net loss: US$193.3m (loss widened 80% from 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Buying Opportunity • Apr 26Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 52%. The fair value is estimated to be €0.95, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 36%. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings is also forecast to grow by 31% per annum over the same time period.
Reported Earnings • Mar 18Full year 2022 earnings released: US$1.65 loss per share (vs US$0.93 loss in FY 2021)Full year 2022 results: US$1.65 loss per share (further deteriorated from US$0.93 loss in FY 2021). Revenue: US$269.8m (down 21% from FY 2021). Net loss: US$528.5m (loss widened 95% from FY 2021). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Mar 18No longer forecast to breakevenThe 6 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$114.3m in 2025. New consensus forecast suggests the company will make a loss of US$43.8m in 2025.
공지 • Jan 31Amyris Launches 4U by Tia™ Haircare Line Exclusively At WalmartAmyris, Inc. announced the launch of 4U by TiaTM, a new haircare line available exclusively at Walmart. Founded by actress and entrepreneur Tia Mowry, 4U by Tia will be sold in over 2,800 Walmart retail stores in the U.S, on Walmart.com, and on the direct-to-consumer website 4UbyTia.com. Amyris will be operating the brand as part of its clean beauty portfolio of brands. The brand is launching with a full line of eight products formulated for 2A to 4C (curly) hair, all of which contain Amyris' patented Hemi15TM, a breakthrough ingredient that nourishes and protects textured hair. The line is 100% vegan, silicone-free, sulfate-free and paraben-free. Hemi15 is created using Amyris' proprietary Lab-to-Market platform, which leverages precision fermentation to create molecules that are bioidentical to those found in nature and traditionally derived from finite sources (including animals, plants, or petrochemicals) to create sustainable ingredients and provide better, healthier options for the products people use every day.
Breakeven Date Change • Nov 16No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$28.4m in 2024.
Breakeven Date Change • Nov 11No longer forecast to breakevenThe 7 analysts covering Amyris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.18m in 2024. New consensus forecast suggests the company will make a loss of US$78.1m in 2024.
Reported Earnings • Nov 10Third quarter 2022 earnings released: US$0.50 loss per share (vs US$0.11 loss in 3Q 2021)Third quarter 2022 results: US$0.50 loss per share (further deteriorated from US$0.11 loss in 3Q 2021). Revenue: US$71.1m (up 49% from 3Q 2021). Net loss: US$161.4m (loss widened 390% from 3Q 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Nov 09Forecast to breakeven in 2024The 7 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 45% per year to 2023. The company is expected to make a profit of US$54.2m in 2024. Average annual earnings growth of 88% is required to achieve expected profit on schedule.
Recent Insider Transactions • Sep 09CFO & Chief Administration Officer recently sold €74k worth of stockOn the 2nd of September, Hermanus Kieftenbeld sold around 26k shares on-market at roughly €2.86 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €116k. Hermanus has been a net seller over the last 12 months, reducing personal holdings by €150k.
Recent Insider Transactions • Aug 18President recently bought €68k worth of stockOn the 15th of August, John Melo bought around 17k shares on-market at roughly €3.96 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, John has been a net seller over the last 12 months, reducing personal holdings by €48k.
Reported Earnings • Aug 11Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.048 profit in 2Q 2021)Second quarter 2022 results: US$0.34 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$65.2m (up 25% from 2Q 2021). Net loss: US$110.0m (down US$125.4m from profit in 2Q 2021). Over the next year, revenue is forecast to grow 91%, compared to a 3.6% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 11Forecast to breakeven in 2024The 8 analysts covering Amyris expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of US$7.18m in 2024. Average annual earnings growth of 79% is required to achieve expected profit on schedule.
Recent Insider Transactions • Jul 09President recently sold €116k worth of stockOn the 6th of July, John Melo sold around 56k shares on-market at roughly €2.08 per share. This was the largest sale by an insider in the last 3 months. This was John's only on-market trade for the last 12 months.
Recent Insider Transactions • Jun 06CFO & Chief Administration Officer recently sold €76k worth of stockOn the 2nd of June, Hermanus Kieftenbeld sold around 35k shares on-market at roughly €2.18 per share. This was the largest sale by an insider in the last 3 months. Hermanus has been a seller over the last 12 months, reducing personal holdings by €382k.
공지 • May 04Amyris, Inc. to Report Q1, 2022 Results on May 10, 2022Amyris, Inc. announced that they will report Q1, 2022 results Pre-Market on May 10, 2022
공지 • Apr 24Amyris, Inc. (NasdaqGS:AMRS) entered into an Agreement and Plan of Merger and Reorganization to acquire Onda Beauty Inc.Amyris, Inc. (NasdaqGS:AMRS) entered into an Agreement and Plan of Merger and Reorganization to acquire Onda Beauty Inc. on April 11, 2022. The consideration consists of 907,946 shares of the common stock of Amyris, Inc. Fenwick & West LLP acted as legal advisor for Amyris.
공지 • Apr 12Amyris, Inc., Annual General Meeting, May 27, 2022Amyris, Inc., Annual General Meeting, May 27, 2022, at 14:00 Pacific Standard Time. Agenda: To consider election of three Class III Directors to serve for a three-year term; to consider ratification of the appointment of Independent Registered Public Accounting Firm; and to consider approval of amendment to Certificate of Incorporation to increase authorized shares.
공지 • Mar 04Amyris, Inc. announced delayed annual 10-K filingOn 03/02/2022, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Feb 24Amyris, Inc. to Report Q4, 2021 Results on Mar 01, 2022Amyris, Inc. announced that they will report Q4, 2021 results Pre-Market on Mar 01, 2022
공지 • Feb 10Amyris, Inc. (NasdaqGS:AMRS) completed the acquisition of 70% of EcoFabulous Cosmetics.Amyris, Inc. (NasdaqGS:AMRS) agreed to acquire 70% of EcoFabulous Cosmetics on April 15, 2021. Marissa will join Amyris to lead brand innovation and be the Chief Creative Officer for the EcoFabulous brand. Amyris, Inc. (NasdaqGS:AMRS) completed the acquisition of 70% of EcoFabulous Cosmetics on February 9, 2022.
공지 • Dec 11Federman & Sherwood Announces Certification of Securities Class Action Lawsuit Against Amyris, IncFederman & Sherwood announced that on December 8, 2021, a class action lawsuit was certified in the United States District Court for the Northern District of California against Amyris, Inc. its CEO John Melo, and its former CFO Kathleen Valiasek. The court certified a Class of investors who purchased shares of Amyris, Inc. common stock during the period from March 15, 2018 through March 19, 2019 (the Class Period) and who were damaged thereby. The lawsuit alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations that defendants issued a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period. The lawsuit seeks to recover damages on behalf of Amyris, Inc. investors who purchased common stock during the Class Period and are therefore a member of the Class.
공지 • Nov 24Amyris, Inc. Provides Revenue Guidance for the Full Year 2021Amyris, Inc. provides revenue guidance for the full year 2021. For the year, the company expects revenue estimate of $330 million to $370 million.
공지 • Aug 27Amyris, Inc. and Jonathan Van Ness Launch JVN Hair A Transformation in Clean Hair ProductsAmyris, Inc. announced the launch of JVN™, a clean hair products brand. The launch is the third of three highly anticipated brand launches Amyris is introducing to the market this summer. The JVN haircare line is a collaboration between Amyris and Jonathan Van Ness: hair stylist, Emmy-nominated television personality, New York Times best-selling author and podcaster. The JVN line sees all beauty, serves all beauty and honors the uniqueness of each person. The JVN collection features four accessibly priced, best performing in category product families that are silicone-free, color-safe, sulfate-free, cruelty-free, and vegan: Nurture, for hair that deserves extra moisture; Undamage, for hair that is stressed or overtreated, Embody, for fine hair with big dreams; and Complete, for hair that is ready to style.
공지 • Aug 25+ 1 more updateAmyris, Inc. (NasdaqGS:AMRS) completed the acquisition of MG Empower Ltd.Amyris, Inc. (NasdaqGS:AMRS) entered into an agreement to acquire Mg Empower Limited on August 11, 2021. In a related transaction, Amyris, Inc entered into an Plan of Merger and Reorganization with OLIKA Inc and Note Purchase Agreement with Olika. Amyris, Inc. (NasdaqGS:AMRS) completed the acquisition of MG Empower Ltd on August 24, 2021.
공지 • Aug 21Amyris Achieves Promising In-Vivo Results For Intranasal Delivery Of RNA/NLC VaccineAmyris, Inc. announced promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute (IDRI). Current mRNA vaccine technologies are providing limited immunity protection for the upper respiratory system. As a result, vaccinated people may experience viral replication and viral shedding regardless of variants. In-vivo results indicate that, when delivered to the mucosal membranes via intranasal administration, the Amyris/IDRI RNA vaccine generates antibodies and provides upper respiratory protection for SARS-CoV-2 (COVID-19), which Amyris believes has the potential to provide fuller protection against current variants of SARS-CoV-2. The Amyris/IDRI RNA technology may also support the potential for intranasal vaccine delivery that can protect against SARS-CoV-2 and other respiratory diseases, including the flu. If approved and commercialized, the Amyris/IDRI RNA vaccine is targeted to be more accessible to people in underserved countries. In addition, the intranasal vaccine may offer improved upper respiratory protection beyond currently approved vaccines. Amyris will provide a detailed update of the progress of its vaccine platform and a roadmap for scale up and delivery during one of its upcoming investor mini-series webinars.
공지 • Aug 20+ 1 more updateAmyris, Inc. (NasdaqGS:AMRS) entered into an agreement to acquire Mg Empower Limited.Amyris, Inc. (NasdaqGS:AMRS) entered into an agreement to acquire Mg Empower Limited on August 11, 2021. In a related, transaction Amyris, Inc entered into an Plan of Merger and Reorganization with OLIKA Inc and Note Purchase Agreement with Olika.
공지 • Jun 28+ 2 more updatesAmyris, Inc.(NasdaqGS:AMRS) dropped from Russell Microcap Growth IndexAmyris, Inc.(NasdaqGS:AMRS) dropped from Russell Microcap Growth Index
